BiopharmaTrend.com

A fresh viewpoint on drug discovery, pharma, and biotech

Become an author | Log in

Topic: ‘Thought-provoking’

Section: Featured Research     View all sections


Outsourcing AI For Drug Discovery: Independent Expertise Is Key To Avoid Overhyped Claims

   by Mostapha Benhenda    1680
Outsourcing AI For Drug Discovery: Independent Expertise Is Key To Avoid Overhyped Claims

Investments in artificial intelligence (AI) for drug discovery are surging. Big Pharmas are throwing big bucks at AI. Sanofi signed a 300 Million dollars deal with the Scottish AI startup Exscentia, and GSK did the same for 42 Million dollars. Also, the Silicon Valley VC firm Andreessen Horowitz launched a new 450 Million dollars bio investment fund, with one focus area in applications of AI to drug discovery.

In this craze, lots of pharma and biotech decision-makers wonder whether they should jump on the bandwagon, or wait and see.

Further Reading